Market closed
Cytokinetics/$CYTK
Cytokinetics shares are trading lower following news of an investigation into potential securities fraud violations.
6 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytokinetics
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Ticker
$CYTK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
498
Website
Cytokinetics Metrics
BasicAdvanced
$5.1B
-
-$5.26
0.94
-
Price and volume
Market cap
$5.1B
Beta
0.94
52-week high
$68.44
52-week low
$32.74
Average daily volume
2.2M
Financial strength
Current ratio
6.166
Quick ratio
5.989
Long term debt to equity
-650.932
Total debt to equity
-681.959
Interest coverage (TTM)
-6.20%
Management effectiveness
Return on assets (TTM)
-30.11%
Return on equity (TTM)
226.00%
Valuation
Price to revenue (TTM)
260.157
Price to book
-37.48
Price to tangible book (TTM)
-37.48
Price to free cash flow (TTM)
-12.021
Growth
Revenue change (TTM)
145.34%
Earnings per share change (TTM)
-3.44%
3-year revenue growth (CAGR)
-35.99%
3-year earnings per share growth (CAGR)
23.42%
What the Analysts think about Cytokinetics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cytokinetics stock.
Cytokinetics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cytokinetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cytokinetics News
AllArticlesVideos
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
Benzinga·6 hours ago
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm
Business Wire·6 hours ago
Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
Business Wire·10 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cytokinetics stock?
Cytokinetics (CYTK) has a market cap of $5.1B as of May 03, 2025.
What is the P/E ratio for Cytokinetics stock?
The price to earnings (P/E) ratio for Cytokinetics (CYTK) stock is 0 as of May 03, 2025.
Does Cytokinetics stock pay dividends?
No, Cytokinetics (CYTK) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Cytokinetics dividend payment date?
Cytokinetics (CYTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytokinetics?
Cytokinetics (CYTK) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.